Myovant Sciences Price to Sales Ratio 2017-2022 | MYOV

Historical PS ratio values for Myovant Sciences (MYOV) over the last 10 years. The current P/S ratio for Myovant Sciences as of May 27, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Myovant Sciences P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-05-27 10.84 4.35
2022-03-31 13.32 $2.49 5.34
2021-12-31 15.57 $2.15 7.25
2021-09-30 22.44 $1.58 14.20
2021-06-30 22.77 $0.74 30.91
2021-03-31 20.58 $0.66 31.09
2020-12-31 27.62 $0.39 71.08
2020-09-30 14.05 $0.37 37.64
2020-06-30 20.62 $0.37 55.24
2020-03-31 7.55 0 0.00
2019-12-31 15.52 0 0.00
2019-09-30 5.20 0 0.00
2019-06-30 9.05 0 0.00
2019-03-31 23.87 0 0.00
2018-12-31 16.41 0 0.00
2018-09-30 26.55 0 0.00
2018-06-30 22.87 0 0.00
2018-03-31 21.27 0 0.00
2017-12-31 12.64 0 0.00
2017-09-30 15.47 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.033B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00